title: How we treat tumor lysis syndrome.
abstract: Tumor lysis syndrome (TLS) is an oncology emergency that occurs as a result of rapid tumor cell breakdown and the consequent release of massive amounts of intracellular contents, including potassium, phosphate, and uric acid, into the systemic circulation. These metabolic disturbances lead to life-threatening conditions and may cause sudden death if not treated. TLS commonly occurs following initiation of cytotoxic treatment in patients with high-grade lymphomas or acute lymphoblastic leukemia. Spontaneous cases involving both solid and hematologic tumors have also been reported. Rarely, TLS occurs following treatment with irradiation, corticosteroids, hormonal therapy, or biologic therapy. It is necessary to identify patients at risk for TLS early in order to initiate preventive measures. In the event that preventive measures fail, the clinical parameters and signs of TLS must be understood and recognized so that treatment can begin as soon as possible, as this condition is a significant cause of morbidity and mortality.
authors: Department ofHematology/Oncology, Oakland University William Beaumont School of Medicine, Royal Oak, Michigan, USA. alaa.muslimani@beaumont.edu
authors: Alaa
authors: A
authors: Muslimani
authors: Mohammad Muhsin
authors: MM
authors: Chisti
authors: Shannon
authors: S
authors: Wills
authors: Laura
authors: L
authors: Nadeau
authors: Dana
authors: D
authors: Zakalik
authors: Hamed
authors: H
authors: Daw
authors: James
authors: J
authors: Huang
authors: Ishmael
authors: I
authors: Jaiyesimi